Publications
This list contains core publications from each of our development programs, but it is not comprehensive. If you would like to take a deeper dive in any of our programs, please contact us.
, WCI, November 2024
"Barzolvolimab Demonstrates Safety and Clinically Meaningful Activity in Moderate-Severe Prurigo Nodularis"
, EADV, October 2023
"Patients With Chronic Spontaneous Urticaria Experience Improvement in Quality of Life When Treated With Barzolvolimab"
, EAACI, June 2023
"Barzolvolimab Demonstrates Clinical Activity in Antihistamine Refractory Cholinergic Urticaria"
, EAACI, June 2023
"Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria"
, AAAAI, February 2023
"Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria"
, GUF, December 2022
"Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab"
, GUF, December 2022
"Barzolvolimab-induced response and mast cell suppression are durable and linked"
, GUF, December 2022
"Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria"
, Allergy, December 2022
"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria"
, SITC, November 2022
"Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab"
, EAACI, July 2022
"Effects of Multiple Dose Treatment with an Anti-KIT Antibody, CDX-0159, in Chronic Spontaneous Urticaria"
, Allergy, February 2022
"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study"
, AAAAI, February 2022
"The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria"
, SITC 2021, November 2021
"CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways"
, EADV, September 2021
"CDX-0159, an anti-KIT Antibody, Demonstrates Rapid and Sustained Clinical Response and Improved Quality of Life in Patients with Chronic Inducible Urticaria"
, EAACI, July 2021
"The Anti-kit Antibody, CDX-0159, Reduces Disease Activity and Tryptase Levels in Patients with Chronic Inducible Urticaria"
, ASCO 2021 Poster, June 2021
"A Phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"
, AACR 2021 Poster, April 2021
"Simultaneous De-repression of Innate and Adaptive Immune Responses Through Dual Targeting of ILT4 and PD-(L)1 with Bispecific Antibodies"
, SITC 2020 Poster, November 2020
"CDX527-01, a Phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"
, SITC 2020 Poster, November 2020
"CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)"
, SITC 2020 Poster, November 2020
"An Axl-targeting Monoclonal Antibody that Inhibits Axl Activity and Potently Stimulates the Innate Immune Response"
, EAACI, June 2020
"CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma Tryptase and a favorable safety profile in a Phase 1a healthy volunteer study"
, Cancer Immunology, Immunotherapy, May 2020
"Development of CDX‑527: a bispecific antibody combining PD‑1 blockade and CD27 costimulation for cancer immunotherapy"
, SITC 2019 Poster, November 2019
"Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies"
, SITC 2019 Poster, November 2019
"Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers"
, ACAAI, November 2019
"CDX-0159, an anti-KIT monoclonal antibody, as a modulator of mast cell-related diseases"
, August 2019
"Conditioning Treatment with a CD27 Antibody Enhances in vivo Expansion and Antitumor Activity of Adoptively Transferred T Cells"
, AACR 2019 Presentation, April 2019
"Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA"
, AACR 2019 Poster, April 2019
"CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1"
, AACR 2018 Poster, April 2018
"Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models"
, AACR 2019 Poster, April 2019
"First-in-human Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results"
, November 2018
"Anti-CD27 agonist antibody varlilumab in combination with nivolumab for recurrent glioblastoma: Phase 2 Clinical Trial Results"
, SITC 2018 Poster, November 2018
"Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140"
, AACR 2018 Presentation, April 2018
"FLT3 Ligand (CDX-301) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer"
, AACR 2018 Poster, April 2018
"Development of novel bispecific immune modulating antibodies"
, ASH 2016 Poster, December 2016
"CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity"
, Society for Immunotherapy of Cancer, November 2017
"Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy"
, June 2017
"Clinical Results with Combination of Anti-CD27 Agonist Antibody, Varlilumab, with Anti-PD1 Antibody, Nivolumab, in Advanced Cancer Patients"
, Journal of Clinical Oncology, May 2017
"Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors"
, April 2016
"Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events"
, SITC 2016 Poster, November 2016
"Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy"
, AACR 2016 Poster, April 2016
"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy"
, AACR 2016 Poster, April 2016
"Development and characterization of novel CD40 antibody agonists for cancer immunotherapy"
, ASBMT 2016 Poster, February 2016
"Preliminary Safety and Efficacy Data using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-matched Sibling Donor Transplantation"
, SITC 2015 Poster, November 2015
"The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent"
, Journal for ImmunoTherapy of Cancer, August 2015
"Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"
, AACR 2015 Poster, April 2015
"Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site"
, Bone Marrow Transplantation, April 2015
"Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers"
, SITC 2014 Poster, November 2014
"Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity"
, ASCO 2014 Poster, June 2014
"Phase I Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab [CDX-1127]) in Patients with Advanced Hematologic Malignancies"
, ASCO 2014 Poster, June 2014
"Immunological Activity of an Activating Anti-CD27 Antibody (Varlilumab [CDX-1127]) in Patients with Solid Tumors"
, OncoImmunology, January 2014
"Targeting human CD27 with an agonist antibody stimulates T cell activation and antitumor immunity"
, SITC 2013 Poster, November 2013
"Combination Therapies Augment the Anti-Tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models"
, SITC 2013 Poster, November 2013
"A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors"
, SITC 2013 Poster, November 2013
"A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors"
, Journal of Immunology, September 2013
"Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice"
, AACR 2013 Poster, April 2013
"Characterization of the Response of Human T cells to an Agonistic Anti-CD27 mAb"
, BMT 2013 Presentation, February 2013
"A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers"
, ASH 2012 Poster, December 2012
"A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers"
, Clinical Cancer Research, May 2012
"Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia"
, AACR 2012 Poster, April 2012
"Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model"
, ASH 2011 Poster, December 2011
"Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms"
, AACR 2011 Poster, April 2011
"Anti-tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model"
, AACR 2010 Poster, April 2010
"Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential"